Hone Health has announced a partnership with BodySpec to incorporate clinical-grade DEXA body composition scans into its telehealth platform, expanding its diagnostic capabilities within longevity-focused care. The integration enables patients to purchase scans directly through the Hone app, access their results within the platform, and receive clinician-guided interpretation and care planning.
BodySpec’s DEXA scans provide detailed measurements including lean muscle mass, visceral fat, resting metabolic rate, bone density, and both total and regional body fat. By embedding these insights into its existing infrastructure, Hone Health aims to offer a more comprehensive view of patient health beyond traditional metrics.
The partnership allows physicians on the Hone platform to combine DEXA scan results with other diagnostic inputs, such as hormone levels and metabolic biomarkers, to refine treatment strategies. This integrated approach is intended to support earlier identification of potential health risks and enable more precise, individualized interventions.
Saad Alam, founder and CEO of Hone Health, emphasized the limitations of conventional measures in evaluating health. “Weight alone doesn't reveal how metabolically healthy someone is,” he said. “BodySpec's DEXA scans show whether a patient is losing fat, gaining muscle, or losing bone density. When our physicians can see that data alongside hormone and metabolic markers, they can adjust treatment earlier and more accurately. That's what connected longevity care looks like.”
The collaboration reflects broader shifts in healthcare toward preventative models and longevity science. Hone Health, an AI-enabled telehealth provider, has positioned itself within this trend by integrating diagnostics, imaging, and physician oversight into a unified platform.
Investor interest in the space has grown alongside these developments. In 2025, Hone Health completed a $33 million Series A funding round, bringing its total funding to $39 million.
Industry analysis, including research from Deloitte, indicates a transition from disease-specific treatment toward addressing the biological processes of aging. This shift is contributing to the emergence of a longevity-focused ecosystem that includes biotech firms, digital health companies, and research institutions, with increasing emphasis on extending health span through preventative and data-driven care models.
Click here for the original news story.
